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ABSTRACT
Pneumococcal parapneumonic empyema is an increasingly common complication in children.
Conventional microbiological cultures indicate bacterial causes in as few as 8% of cases; therefore,
there is a vital need for new molecular methods of detection and diagnosis. The development and
clinical evaluation of real-time PCR-based assays to detect the pneumococcal capsular wzg gene of all
serotypes tested are reported here, and 24 of them have been identified in clinical specimens. Using real-
time PCR assays with highly specific TaqMan MGB probes that target DNA sequences within the
capsular polysaccharide gene cluster, it was possible to differentiate serotypes 1, 3, 5, 4, 6A, 6B, 7F ⁄A, 8,
9V ⁄A ⁄N ⁄L, 14, 15B ⁄C, 18C ⁄B, 19A, 19F ⁄B ⁄C, 23F and 23A. These assays showed high sensitivity (five to
ten pneumococcal DNA equivalents) and they were validated with 175 clinical isolates of known
serotypes. The clinical value of this approach was demonstrated by analysis of 88 culture-negative
pleural fluids from children diagnosed with parapneumonic empyema in three Spanish hospitals.
Pneumococcal DNA was detected in 87.5% of pleural fluids, and serotypes 1, 7F and 3 were responsible
for 34.3%, 16.4% and 11.9%, respectively, of cases of parapneumonic empyema in children. Such
molecular methods are critical for the diagnosis of invasive pneumococcal disease and continued
epidemiological surveillance in order to monitor serotype vaccine effectiveness.
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INTRODUCTION
Pneumococcal serogroup and serotype identifica-
tion is currently performed by various methods
involving large panels of expensive antisera,
including the capsular swelling (Quellung) reac-
tion (the traditional reference standard), latex
agglutination and co-agglutination [1], and a dot
blot assay [2]. However, each of these methods
requires clinical isolates. As the yield of micro-
biological diagnostics can be as low as 8% for
pleural fluids (PFs) [3] and <10% for blood [4],
there is a basic need for typing methods that do
not rely on clinical isolates. Recently, a conven-
tional multiplex PCR approach for routine sur-
veillance has been developed [5]. The advantages
of real-time PCR over conventional PCR are its
speed (elimination of the need for postprocessing
steps that could contribute to contamination) and
its wider dynamic range (allowing detection of
much larger variations in concentrations of the
target). The most important advantage is the
lower limit of detection. The higher analytical
sensitivity of real-time PCR TaqMan assays, as
compared with conventional methods, would also
facilitate simultaneous identification of more than
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one serotype [6]. Real-time PCR-based methods
for diagnosis and serotyping would represent a
valuable tool to improve current methods of
microbiological diagnosis and epidemiological
surveillance of both pneumococcal infections
and nasopharyngeal colonization [7].
One question with PCR-based detection meth-
ods is how to validate that a culture-negative,
PCR-positive result, especially with ply, repre-
sents the actual presence of pneumococci. One
way to enhance confidence in the initial PCR
result would be to test samples using a second
PCR that targets an unrelated gene. Therefore, in
the present study, the wgz real-time PCR assay
was used in a dual-target approach and run in
parallel with the current pneumolysin PCR assay.
In this study, novel, sensitive and specific real-
time PCR assays for the detection of all pneu-
mococci and for the specific identification of
serotypes, or serogroups, 1, 3, 4, 5, 6A, 6B, 7F ⁄A,
8, 9V ⁄A ⁄N ⁄L, 14, 15B ⁄C, 18C ⁄B, 19A, 19F ⁄B ⁄C,
23A, and 23F are described. The extensive strain
collection of the Spanish Reference Laboratory of
Pneumococci was exploited to thoroughly evalu-
ate the specificity of these new assays. Moreover,
these assays successfully detected and identified
pneumococcal serotypes in a large number of
culture-negative PFs collected from children with
parapneumonic empyema (PE). This work under-
scores the importance of ongoing serotype
surveillance studies using molecular methods.
MATERIALS AND METHODS
Clinical isolates and conventional serotyping
Pneumococcal clinical isolates of known serotype and non-
pneumococcal isolates (Streptococcus mitis, S. oralis and
S. gordonii; two strains each) from the collection of the Spanish
Reference Laboratory of Pneumococci were used to assess the
species and the serotype or serogroup specificity and sensitiv-
ity of the real-time PCR assays. One hundred and seventy-five
clinical isolates representing 35 serotypes (1, 2, 3, 4, 5, 6A, 6B,
7F, 7A, 8, 9V, 9N, 9A, 10A, 10F, 11A, 12F, 13, 14, 15B, 15C, 16F,
17F, 18C, 19A, 19F, 20, 22F, 23F, 23A, 23B, 24A, 33F, 34, 37), five
strains each, were serotyped by conventional methods. This
serotype panel was chosen because it comprised 95.2% of
serotypes of all invasive pneumococcal isolates received at the
Spanish Reference Laboratory of Pneumococci during 2006.
Isolates retrieved from storage by subculture on blood agar
plates (Columbia II agar base supplemented with 5% horse
blood) were incubated overnight at 37C in 5% CO2. Conven-
tional serotyping was performed by the Quellung reaction
using rabbit polyclonal antisera from the Statens Serum
Institute, Copenhagen, Denmark as previously described [1].
Dot blot serotyping was performed as previously described [2].
Culture-negative PF specimens
This study retrospectively evaluated 88 culture-negative PF
samples of paediatric patients who were diagnosed with PE
during 2003–2006 in three Spanish hospitals (Hospital Univer-
sitario Virgen del Rocı´o, Sevilla; Hospital Carlos Haya,
Ma´laga; and Hospital Sant Joan de Deu, Barcelona) These
were derived from 118 culture-negative PF samples that had
been collected and stored at )80C at participating hospitals
during the study period. Genotyping by multilocus sequence
typing was initially performed in these clinical samples in
Oxford, Seville and Barcelona, and proved to be a difficult
assay that often required multiple and repeated testing,
leaving only 88 specimens for further molecular testing. The
median patient age was 47 months (range 11–180 months) and
the male ⁄ female ratio was 1.09 : 1. The median duration of
symptoms before thoracocentesis was 6 days (range
3–23 days). Eighty-two of 88 children (93.2%) had received
antibiotic treatment prior to PF sampling (oral and ⁄ or paren-
teral). According to parental report, 29 ⁄ 88 (32.9%) of patients
had received at least one dose of PCV7.
Selection of the capsular gene as a target for real-time PCR
assay for the detection of pneumococci
All published DNA sequences of the capsular polysaccharide
gene cluster comprising 90 pneumococcal serotypes [8] and
related a-haemolytic streptococci (S. mitis, S. oralis and
S. gordonii), located with BLAST (Basic Local Alignment Search
Tool) [9] and downloaded from the GenBank database (http://
www.ncbi.nlm.nih.gov/genbank/), were analyzed. A PCR
primer pair and TaqMan minor groove binder (MGB) probe
targeting the most highly conserved capsular gene in pneu-
mococci, the cpsA or wzg gene [10], were selected for the
detection of pneumococcal DNA by real-time PCR.
Selection of capsular genes as targets for real-time PCR
typing assays and group design
Molecular typing was based on serotypes assigned by conven-
tional serotyping. Sequences for each serotype and each capsu-
lar gene were searched with BLAST for all similar sequences
in the GenBank database (http://www.ncbi.nlm.nih.gov). All
retrieved sequences were re-aligned and analyzed by MEGALIGN
(Lasergene v7.2; DNASTAR Inc., Madison, WI, USA) and
MACAW software (National Center for Biotechnology Informa-
tion, National Library of Medicine, version 2.0.5) to reveal
gene-specific differences in sequence conservation between
serotypes. Consequently, all 90 serotypes were grouped for
each capsular gene according to sequence similarity. Target
genes were selected to distinguish polymorphisms among
relevant serotypes PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F and
23F), the 10-valent and 13-valent vaccines serotypes that add to
PCV7 emerging or replacing serotypes in IPD [11] such as 1, 3,
5, 6A, 7F and 19A (Table 1).
Primers for the PCR typing assays allowed serotype
grouping according to sequence similarity and relevance of
serotype; for example, a duplex real-time PCR assay for
serotypes 1 and 5 was designed on the basis of sequence
similarity of the ugd gene and the observation that both
serotypes are highly prevalent in children with PE [12].
A single real-time PCR was designed for serotype 3, because
genes within its capsular locus are either highly conserved
(wzg) or specific (cap3B; wchE; cps3S). Using real-time PCR for
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typing serotypes 6A and 6B, it was possible to detect a single
non-synonymous polymorphism at codon 195 within wciP, the
rhamnosyl transferase gene, which has previously been shown
to be responsible for the expression of serotype 6A or 6B [13].
Both this non-synonymous polymorphism and an additional
one are included in the specific 6A and 6B TaqMan MGB
probes. Furthermore, where possible, the more prevalent
serotypes in some specimens of IPD were combined in a
single real-time PCR assay. Some serotypes were indistin-
guishable from other closely related serotypes, most of which
belonged to the same serogroup (Table 1). Groups of serotypes
analyzed by real-time PCR assays and selected genes of each
group are shown in Table 1.
Oligonucleotide primers and TaqMan MGB probe designs
In the preliminary analysis of sequences, very minor variability
within different strains of the same serotype (a few nucleotides
throughout the whole gene sequence) were found. Specifically
designed primers and probes were therefore created to avoid
those variable positions in sequences. Consensus or degenerate
oligonucleotide primers and probes were designed for each
real-time PCR group using PRIMER EXPRESS 3.0 (Applied Bio-
systems, Applera Hispania SA, Tres Cantos, Madrid, Spain).
Serotype-specific TaqMan MGB probes were labelled with
FAM or VIC fluorochromes. Primers were synthesized by
Sygma-Genosys (Cambridge, UK) and probes by Applied
Biosystems (Applera Hispania SA). The oligonucleotide
primers and probes used in this study, their target genes,
specificity, sequences, and the numbered base positions of
probes are shown in Table 1.
DNA extraction from clinical specimens and clinical isolates
DNA was extracted from 200 lL of PF using the QIAamp
DNA mini kit (Qiagen, Izasa, Barcelona, Spain) according to
the protocol provided by the manufacturer. This protocol
minimizes the presence of PCR inhibitors in the final sample.
DNA was isolated from serotyped clinical isolates by suspen-
sion of S. pneumoniae strains at 0.1 MacFarland unit in MilliQ
water, heated to 90C for 30 min, and subsequently cooled on
ice and centrifuged for 5 min at 5000 g. to pellet non-disrupted
bacteria and cell debris. DNA samples were stored at )20C.
The concentrations of the DNA extracted from the bacterial
cultures were determined by the Nanodrop method (Nano-
drop Technologies, Wilmington, Delaware, USA). A 2.5-lL
aliquot of supernatant containing free DNA was used as the
template for PCR.
Pneumolysin gene PCR assay for the detection of
pneumococci
Detection of pneumococci in PF was performed by a previ-
ously described method based on PCR with ply [4].
Real-time PCR assay for the detection of pneumococci and
real-time PCR assays for serotype determination
Standard real-time PCR conditions recommended by the
manufacturer were used in all experiments, with minor
modifications. Real-time PCR assays were carried out in a
final 25-lL reaction volume in optical tubes or on optical
96-well plates (Applied Biosystems), depending on the
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number of samples to be tested per run. All assays with each
sample were performed in triplicate, using the Master Mix
PCR without AmpErase UNG 2X (Applied Biosystems),
according to the instructions of the manufacturer, with
2.5 lL of sample DNA. The primer and probe concentrations
for each of the 11 assays were optimized, and, in accordance
with the experimentally optimized concentrations, 900 nM
primers and 200 nM TaqMan MGB probes were used for all
subsequent experiments. A non-template control and the
corresponding serotype-positive DNA control chosen from
the serotype panel were included in every run. DNA was
amplified with the Applied Biosystems 7300 Real-time PCR
System (Applied Biosystems) by using the following cycling
parameters: 95C for 10 min, followed by 40 cycles at 95C for
15 s and 60C for 1 min (total time: 1 h 45 min). Amplification
data were analyzed by instrument software (SDS, Applied
Biosystems). Negative results were defined as those with cycle
threshold (CT) values >40. A sample was considered positive if
at least two of three yielded a positive result within the <40-
cycle cut-off. For assessments of the lower limits of detection,
serial ten-fold dilutions (equivalent to from c. 5000 to five
bacteria) of purified DNA from the corresponding serotype-
positive DNA control, chosen from the serotype panel, were
prepared, and aliquots were tested using all 11 real-time
PCR protocols. Specificity determinations were made by
testing at 5 mg ⁄L the DNAs extracted from all S. pneumoniae
isolates of the serotype panel and six non-pneumococcal
isolates (S. mitis, S. oralis and S. gordonii, two strains each) by
all 11 assays.
RESULTS
Development of a real-time PCR assay for the
detection of the S. pneumoniae wzg gene and
its validation with clinical isolates
A real-time PCR assay was developed for the
detection of a highly specific sequence in the
pneumococcal wzg gene. This assay allowed
the detection of a minimum of 12–24 fg of DNA,
corresponding to five to ten bacteria. Theoretical
analytical specificity was ascertained using a BLAST
[9] search of the probe and primer sequences, in
which no exact match was found with any non-
pneumococcal sequence. DNA from each of 175
pneumococcal strains representing 35 serotypes
(see Materials and methods for a list) was
detected using wzg-targeting real-time PCR with
the same detection limit for each serotype. To test
the analytical specificity of the specific pneumo-
coccal TaqMan MGB probe, DNA from three
related a-haemolytic streptococci carrying homo-
logous, but not identical, wzg genes (two strains
each of S. mitis, S. oralis and S. gordonii) was also
tested. In addition, two culture-positive PFs that
yielded Staphylococcus aureus and S. pyogenes
isolates were tested. No reporter fluorescent
signal was detected with DNA extracted from
any of these non-pneumococcal strains, demon-
strating high specificity of the probe sequence
used.
Development and validation of real-time PCR
assays for the determination of pneumococcal
serotypes or serogroups
Ten groups of real-time PCR typing assays cov-
ering 24 serotypes were developed. In 2006,
80.9% of all invasive isolates received at the
Spanish Reference Laboratory of Pneumococci
belonged to one of these serotypes. The 35
different serotypes, represented by five strains
each, were used to pretest the specificity of the
real-time PCR typing assays. The strains of all the
serotypes included in the assays were correctly
typed by the technique described here, whereas
the strains of serotypes not included were nega-
tive in all real-time PCR typing assays. Although
we believe that the method is largely validated
with the 175 strains, we further note that in ten
cases of culture-positive PE tested, the serotype
determined by the Quellung technique matched
those detected with serotype real-time PCR assays
directly, using the corresponding PF. All PCR
products were analyzed by gel electrophoresis
and yielded amplicons of the expected size, and
the sequencing results perfectly matched the
corresponding published sequences, confirming
the specificity of the real-time PCR assays. All ten
assays allowed the detection of a minimum of
12–24 fg of DNA, corresponding to five to ten
bacteria.
Study of culture-negative PFs from children
with PE
The 88 PF specimens were analyzed using both
ply-targeting and wzg-targeting PCR assays.
Among 88 PFs, 74 were positive using ply PCR
and 72 were positive using wzg real-time PCR.
There were eight discrepancies between the two
assay methods: five samples were ply-positive but
wzg-negative, and three were ply-negative but
wzg-positive. Therefore, putative pneumococcal
DNA (either ply-positive or wzg-positive, or both)
was detected in 77 ⁄ 88 (87.5%) of culture-negative
samples. However, in two of the five ply-positive ⁄
wzg-negative PFs, unrelated pathogens (S. pyogenes
and Stapylococcus aureus) grew, suggesting
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false-positive PCR results. Thus, if 75 PFs represent
the number of true pneumococcal samples, then
the sensitivity of either ply PCR or wzg PCR would
be 72 ⁄ 75 (96%). Overall, among these 75 PFs,
sufficient material was available for serotype real-
time PCR with 67 samples, and the serotype was
successfully identified in 52 samples. Thus, the
maximum specificity of wzg PCR could be as high
as 100%, as there is no evidence that any of the 72
wzg-positive samples were not true pneumococci
and, in fact, two of three ply-negative ⁄wzg-positive
samples could be serotyped, indicating that they
are true pneumococci. Alternatively, if one were to
assume that either being wzg-positive ⁄ ply-positive
or being a serotypeable sample is sufficient to
define a true pneumococcus, then the minimum
specificitywould be 71 ⁄ 72 (98.6%) (wzg+ ⁄ ply+ = 69
plus the proportion of serotypeable samples
among the wzg+ ⁄ ply) samples= 2). Results based
on the 88 PFs are shown in Fig. 1. Serotype
distributions are shown in Table 2.
DISCUSSION
Real-time PCR offers an opportunity to re-
address the problem of the diagnosis of infec-
tions due to S. pneumoniae and to determine the
responsible serotypes. The assays described in
this article proved to be highly sensitive and
specific in detecting and identifying pneumo-
coccal serotype-specific DNA. The serotype real-
time PCR method produced unambiguous
results that perfectly matched Quellung reaction
and dot blot test results. Although DNA from
only 35 of the 90 known serotypes was tested,
the serotype specificity of each group of real-
time PCR was supported by comparison of the
selected gene sequence with the CPS gene
cluster sequences for all 90 known serotypes
available in the GenBank database. Similarly,
the real-time PCR detection assay gave positive
results with the panel of 35 serotypes and
negative results with strains of S. mitis, S. gordo-
nii and S. oralis. As oligonucleotide primers and
probes were designed specifically for S. pneumo-
niae DNA sequences, and did not match any
sequence of Staphylococcus aureus or S. pyogenes,
extensive specificity tests were not included in
the assays for these pathogens. However,
because those are relevant pathogens in other
88 culture-negative pleural fluids
analyzed by PCR  
3 ply –wzg +5 ply +wzg – 11 ply –wzg – 69 ply +wzg –
2 Non  
pneumococci
3 Not 
tested 
1 Not  
tested 
2 + 
serotype
67 available samples analyzed  by
serotype real-time PCR 
4 Not  
tested 
11 Not 
tested 
52 identified 
serotype
15 unknown 
serotype
Fig. 1. Diagrammatic representa-
tion of the molecular analysis of 88
parapneumonic empyema cases
without microbiological pneumo-
coccal isolates. Eighty-eight samples
were tested for pneumococcal DNA
by ply PCR and wzg real-time PCR.
Twenty-one pleural fluid samples
were not tested by serotype real-
time PCR because they were nega-
tive according to both ply PCR and
wzg real-time PCR, they did not
contain pneumococci, or there was
an insufficient amount of sample.
Subsequently, 67 samples were anal-
yzed by serotype real-time PCR, 52
of which were identified to the
serotype level.
Table 2. Molecular study of 67 culture-negative pleural
fluids: results of serotype real-time PCR
Serotype
Serotype real-time PCR; no. of
positive pleural fluids (%)
1 23 (34.3)
3 8 (11.9)
5 2 (2.9)
7F ⁄A 11 (16.4)
8 1 (1.4)
14 3 (4.4)
19A 3 (4.4)
19F ⁄B ⁄C 1 (1.4)
Unknowna 15 (22.3)
Total 67 (100)
aUnknown indicates that the serotype could not be identified by real-time PCR as
one of the 24 serotypes.
832 Clinical Microbiology and Infection, Volume 14 Number 9, September 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 828–834
areas and Staphylococcus aureus has recently
emerged as the leading cause of PE in certain
areas of the USA [14], it is worth noting that
two cases of PE in which the PFs yielded
Staphylococcus aureus and S. pyogenes, respec-
tively, both gave negative results using wzg
real-time PCR. Although there are many reports
of false-positive ply-targeted PCRs [15,16], detec-
tion of both wzg DNA and ply DNA sequences,
combined with real-time PCR serotype identifi-
cation, makes it likely that these are indeed
true-positive results. Furthermore, it seems that
the results of these combined assays could be as
reliable as the combination of the recently
described real-time PCR assays targeting the
lytA, ply and psaA genes for identification of
S. pneumoniae as the aetiological agent of
infections [17].
Carvalho et al. [17] reported that ply-targeted
PCRs showed positive results when pneumococ-
cus-like viridans group streptococci were tested.
In this regard, an additional target on the capsular
wzg gene, exploited by the real-time detection
assay described here, may contribute to clarifying
the molecular identification of S. pneumoniae, par-
ticularly when identification is attempted with
non-sterile specimens such as sputum. However,
it should be noted that because ply PCR was
performed in Seville and Barcelona, the wzg real-
time PCR and serotype real-time PCR assays were
performed retrospectively, using limited volumes
of DNA extracts shipped to the reference labora-
tory in Madrid. Unfortunately, there was not
always sufficient sample volume to repeat the
test. Moreover, as ply PCR and wzg real-time PCR
were always performed sequentially, the samples
to be tested using wzg real-time PCR have been
frozen and thawed more frequently than those
tested with ply PCR. These procedures compro-
mise the quantity and quality of DNA and could
account for some of the few discrepancies among
the methods observed in this study. Therefore, the
possibility that the three ply-positive and wzg-
negative PCRs could also have arisen from
pneumococcus-positive pleural fluids cannot be
conclusively ruled out, and further studies are
needed for clarification.
As the wzg-targeted PCR assay was used to
detect pneumococci in clinical specimens with
potential inhibitors of PCR reactions, it would be
desirable to include an internal control to detect
false negatives. Toward this end, we are working
on an exogenous active reference by constructing
an internal control plasmid that will be used
to distinguish true target negatives from PCR
inhibition.
Routine clinical practices such as administra-
tion of antibiotics prior to thoracocentesis could
conceivably lead to an overestimation of the role
of resistant serotypes in PE, and an underestima-
tion of the importance of susceptible serotypes
such as 1, 3, 5 and 7F. Serotypes 1, 7F and 3 were
detected in 34.3%, 16.4% and 11.9%, respectively,
of the ply-positive or wzg-positive, culture-nega-
tive PE cases, which suggests that these values
more accurately reflect the actual serotype distri-
bution in cases of empyema from our area than
those obtained by conventional non-molecular
methods. In this regard, 47 of the 52 (90.3%)
culture-negative PF samples for which serotype
results were obtained by real-time PCR came
from children who had previously undergone
intravenous antibiotic therapy for a median dura-
tion of 3 days (range 1–10 days). This demon-
strates the ability of this method to detect and
identify the serotype despite prolonged antibiotic
therapy.
The real-time PCR technique described here
would permit analysis of a large number of
clinical specimens in a single day, the scale being
limited by the equipment available. Although the
usefulness of the assays has been demonstrated
with culture-negative pleural fluids, they may be
equally useful for the analysis of culture-negative
cerebrospinal fluid and blood samples. The sim-
plicity and flexibility of this approach mean that it
is likely to be reproducible in other laboratories,
and it should be possible to add more serotypes
by designing new real-time PCR assays using the
same strategy. The application of this technique
has improved the diagnostic and reference activ-
ities of our laboratory, and has extended its
diagnostic capability to culture-negative speci-
mens. We believe that this technique has the
potential to be a robust alternative to serological
serotyping and will be of value to reference
centres and researchers investigating serotype
replacement and the population biology of
S. pneumoniae.
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